Xilio Therapeutics, Inc.
XLO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $6 | $0 | $0 | -$1 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $41 | $52 | $59 | $51 |
| G&A Expenses | $25 | $27 | $30 | $0 |
| SG&A Expenses | $25 | $27 | $30 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $67 | $79 | $89 | $74 |
| Operating Income | -$61 | -$79 | -$89 | -$75 |
| % Margin | -954.9% | – | – | – |
| Other Income/Exp. Net | $2 | $3 | $1 | -$1 |
| Pre-Tax Income | -$58 | -$76 | -$88 | -$76 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$58 | -$76 | -$88 | -$76 |
| % Margin | -918% | – | – | – |
| EPS | -1.09 | -2.78 | -3.19 | -2.72 |
| % Growth | 60.8% | 12.9% | -17.3% | – |
| EPS Diluted | -1.09 | -2.78 | -3.19 | -2.72 |
| Weighted Avg Shares Out | 54 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 54 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$58 | -$77 | -$87 | -$74 |
| % Margin | -914.3% | – | – | – |